Aleks Davis

Aleks Davis has over twenty years of experience in biotechnology industry with a proven track record in multiple facets of drug development. As a project director in Tailored Therapeutics at Eli Lilly and Company, Aleks was responsible for the planning, implementation and financial tracking of projects supporting early stage biomarker hypothesis. Several of these projects were in the neuroscience field. As the global director at ICON PLC, Aleks developed policies and procedures, business development strategies, marketing and profit and loss accountability. There he directed operations spanning four continents. Now at B2S Life Sciences, Aleks is the CEO and works with over one hundred different clients by helping them navigate the important, yet, challenging aspects of bioanalysis in biotherapeutic development. His Chemistry degree is from Georgia Southern University and Executive MBA is from Kelley School of Business, Indiana University. In 2019, he was a member of the B2S Life Sciences team that was honored by the Small Business Administration as Indiana’s Exporter of the Year.